1. Scrip
  2. >>Business
  3. >>Earnings

Lilly Tries To Keep Investors Focused On The Pipeline, Not Performance

 
• By Joseph Haas

With disappointing revenues during Q1 due to the pandemic impact on sales and price pressure on Taltz, the pharma gave a long-term, pipeline-focused growth narrative. Alzheimer's filing plans pushed back.

Lilly
Lilly has increased R&D spending guidance with focus on long-term growth

Eli Lilly and Company primarily used its first quarter 2021 earnings call on 27 April to point out some of its long-term plays, particularly the Alzheimer’s disease candidate donanemab and type 2 diabetes candidate tirzepatide. And it might take a while to deliver on those potentially game-changing opportunities: the pharma revealed that it will not seek accelerated approval of donanemab based on Phase II data.

A lesser focus of the call was on the quarterly performance; while Lilly’s year-over-year sales revenue increased by 16%, several...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

EY Recommends Focusing On Fundamentals, Waiting For Prime Deal Conditions

 
• By Joseph Haas

Government policy ramifications and tight financial markets mean it’s time to prepare strategically for a better business development environment, EY suggests.